ACP
PTGX icon

Acuta Capital Partners’s Protagonist Therapeutics PTGX Stock Holding History

Acuta Capital Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-418,500
Closed -$5.03M – 47
2019
Q3 		$5.03M Sell
418,500
-253,000
-38% -$3.19M 3.63% 10
2019
Q2 		$8.13M Buy
671,500
+334,000
+99% +$3.69M 2.89% 14
2019
Q1 		$4.24M Buy
+337,500
New +$2.98M 2.02% 20

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's PTGX Position: Q4 2019 in Review

Acuta Capital Partners sold out of Protagonist Therapeutics (PTGX) in Q4 2019, closing a stake of 418,500 shares — an estimated $5.03M sold.

Acuta Capital Partners first reported a position in PTGX in Q1 2019 and held it in 3 quarters. The position peaked at $8.13M in Q2 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • Acuta Capital Partners reported no remaining Protagonist Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 418,500 Protagonist Therapeutics shares in Q4 2019, an estimated $5.03M.
  • Acuta Capital Partners first reported a position in Protagonist Therapeutics in Q1 2019 and held it in 3 quarters.
  • Acuta Capital Partners's Protagonist Therapeutics position peaked at $8.13M in Q2 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.